Mueller Lab spun off Apic Bio
martes, agosto 22, 2017
|
Dr. Mueller and the Mueller Lab for Gene Therapy are happy to announce the creation of Apic Bio, a preclinical stage gene therapy company.
The newly formed company leverages its proprietary platform to advance therapies to treat rare diseases with complex mechanisms. Its lead product, APB-101, is targeted at alpha-1 antitrypsin deficiency. Apic Bio raised investments from The Alpha-1 Project (TAP), which is the venture philantropy arm of the Alpha-1 Foundation, and from a private investor with the disease.
Dr. Mueller, Co-founder and Chief Scientific Officer of Apic Bio said: “We are encouraged by the feedback that we have received during our pre-IND meeting with the FDA that there is a clear path for us to conduct a first-in-human Phase 1/2 clinical study. Furthermore, we are very much looking forward to demonstrating the benefit of APB-101 to patients that have been living with alpha-1 and have had very little hope for a cure. Our data suggests this is a ‘liver sparing’ approach for gene augmentation which may exceed the therapeutic and safety margins when compared to a strict gene augmentation without gene silencing that may exacerbate the underlying liver disease.”
See below a selection of the press coverage of the Apic Bio launch.
Boston Globe "For this investor, it’s a life-and-death venture" 08/21/2017
Alpha-1 Foundation "Alpha-1 patient and The Alpha-1 Project join forces to find a new therapy" 08/22/2017
Business Wire "Apic Bio Launches to Advance First-in-Class Gene Therapy for Treatment of Alpha-1 Antitrypsin Deficiency (Alpha 1) --The Alpha-1 Project (TAP) leads syndicate of investors for seed round financing" 08/22/2017
